Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
All content for Beginner's Mind is the property of Christian Soschner and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
EP 162 - Alex Oppenheimer: The Secret Investors Use Before Writing the First Check
Beginner's Mind
1 hour 25 minutes
5 months ago
EP 162 - Alex Oppenheimer: The Secret Investors Use Before Writing the First Check
Here’s the harsh truth: If your business model can’t survive a spreadsheet, it won’t survive the market. Every year, ambitious founders pour months into product, pitch, and brand—yet the single biggest reason startups die isn’t funding, it’s flawed modeling. What are the four variables investors use to spot winners before anyone else? In this episode, investor and hands-on builder Alex Oppenheimer (Founder & GP at Verissimo Ventures, ex-Facebook IPO, ex-NEA, Monday.com advisor) reveals wh...
Beginner's Mind
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
